Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis

2.50
Hdl Handle:
http://hdl.handle.net/2336/48998
Title:
Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis
Authors:
Eiriksdottir, G; Johannesdottir, G; Ingvarsson, S; Bjornsdottir, I B; Jonasson, J G; Agnarsson, B A; Hallgrimsson, J; Gudmundsson, J; Egilsson, V; Sigurdsson, H; Barkardottir, R B
Citation:
Eur. J. Cancer. 1998, 34(13):2076-81
Issue Date:
1-Dec-1998
Abstract:
Several chromosome regions exhibit loss of heterozygosity (LOH) in human breast carcinoma and are thought to harbour tumour suppressor genes (TSG). At chromosome 13q, two TSGs have been identified, RB1 at 13q14 and BRCA2 at 13q12-q13. In this study, 139 sporadic breast tumours were analysed with 18 polymorphic microsatellite markers for detailed mapping of LOH at chromosome 13q and evaluation of an association with known progression factors. LOH with at least one marker was observed in 71 (51%) of the tumours analysed. The deletion mapping indicated three LOH target regions, 13q12-q13, 13q14 and 13q31-q34. LOH at chromosome 13q12-q13 was associated with low progesterone receptor content, a high S phase fraction and aneuploidy. Multivariate analysis adjusting for lymph node involvement and S phase fraction showed that patients with tumours exhibiting LOH at 13q12-q13 have a 3-4-fold increased risk of recurrence and death compared with other patients. Our results suggest there are at least three separate LOH target regions at chromosome 13q and inactivation of one or more genes at chromosome 13q12-q13 results in poor prognosis for breast cancer patients.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.sciencedirect.com/science/article/B6T68-3V7HP7S-M/2/cab24556140262c466cf913a8b2ce4f6

Full metadata record

DC FieldValue Language
dc.contributor.authorEiriksdottir, G-
dc.contributor.authorJohannesdottir, G-
dc.contributor.authorIngvarsson, S-
dc.contributor.authorBjornsdottir, I B-
dc.contributor.authorJonasson, J G-
dc.contributor.authorAgnarsson, B A-
dc.contributor.authorHallgrimsson, J-
dc.contributor.authorGudmundsson, J-
dc.contributor.authorEgilsson, V-
dc.contributor.authorSigurdsson, H-
dc.contributor.authorBarkardottir, R B-
dc.date.accessioned2009-02-12T13:47:30Z-
dc.date.available2009-02-12T13:47:30Z-
dc.date.issued1998-12-01-
dc.date.submitted2009-02-12-
dc.identifier.citationEur. J. Cancer. 1998, 34(13):2076-81en
dc.identifier.issn0959-8049-
dc.identifier.pmid10070314-
dc.identifier.doi10.1016/S0959-8049(98)00241-X-
dc.identifier.urihttp://hdl.handle.net/2336/48998-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractSeveral chromosome regions exhibit loss of heterozygosity (LOH) in human breast carcinoma and are thought to harbour tumour suppressor genes (TSG). At chromosome 13q, two TSGs have been identified, RB1 at 13q14 and BRCA2 at 13q12-q13. In this study, 139 sporadic breast tumours were analysed with 18 polymorphic microsatellite markers for detailed mapping of LOH at chromosome 13q and evaluation of an association with known progression factors. LOH with at least one marker was observed in 71 (51%) of the tumours analysed. The deletion mapping indicated three LOH target regions, 13q12-q13, 13q14 and 13q31-q34. LOH at chromosome 13q12-q13 was associated with low progesterone receptor content, a high S phase fraction and aneuploidy. Multivariate analysis adjusting for lymph node involvement and S phase fraction showed that patients with tumours exhibiting LOH at 13q12-q13 have a 3-4-fold increased risk of recurrence and death compared with other patients. Our results suggest there are at least three separate LOH target regions at chromosome 13q and inactivation of one or more genes at chromosome 13q12-q13 results in poor prognosis for breast cancer patients.en
dc.language.isoenen
dc.publisherElsevier Science Ltden
dc.relation.urlhttp://www.sciencedirect.com/science/article/B6T68-3V7HP7S-M/2/cab24556140262c466cf913a8b2ce4f6en
dc.subject.meshAneuploidyen
dc.subject.meshBRCA2 Proteinen
dc.subject.meshBreast Neoplasmsen
dc.subject.meshChromosome Mappingen
dc.subject.meshChromosomes, Human, Pair 13en
dc.subject.meshDisease-Free Survivalen
dc.subject.meshFemaleen
dc.subject.meshGene Deletionen
dc.subject.meshHumansen
dc.subject.meshLoss of Heterozygosityen
dc.subject.meshMicrosatellite Repeatsen
dc.subject.meshNeoplasm Proteinsen
dc.subject.meshPrognosisen
dc.subject.meshReceptors, Progesteroneen
dc.subject.meshS Phaseen
dc.subject.meshTranscription Factorsen
dc.titleMapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosisen
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology, University and National Hospital of Iceland, Reykjavik, Iceland.en
dc.identifier.journalEuropean journal of cancer (Oxford, England : 1990)en

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.